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Abstract
Wallerian degeneration is delayed when sufficient levels of proteins with NMNAT activity are maintained within axons after
injury. This has been proposed to form the basis of ’slow Wallerian degeneration’ (WldS), a neuroprotective phenotype
conferred by an aberrant fusion protein, WldS. Proteasome inhibition also delays Wallerian degeneration, although much
less robustly, with stabilization of NMNAT2 likely to play a key role in this mechanism. The pan-MEK inhibitor U0126 has
previously been shown to reverse the axon-protective effects of proteasome inhibition, suggesting that MEK-ERK signaling
plays a role in delayed Wallerian degeneration, in addition to its established role in promoting neuronal survival. Here we
show that whilst U0126 can also reverse WldS-mediated axon protection, more specific inhibitors of MEK1/2 and MEK5,
PD184352 and BIX02189, have no significant effect on the delay to Wallerian degeneration in either situation, whether used
alone or in combination. This suggests that an off-target effect of U0126 is responsible for reversion of the axon protective
effects of WldS expression or proteasome inhibition, rather than inhibition of MEK1/2-ERK1/2 or MEK5-ERK5 signaling.
Importantly, this off-target effect does not appear to result in alterations in the stabilities of either WldS or NMNAT2.
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Introduction
Effective therapeutic targeting of Wallerian degeneration and
other types of axon degeneration that share a common molecular
basis (Wallerian-like axon degeneration) could have profound
implications for numerous neurodegenerative diseases where
axonopathy contributes to pathogenesis [1]. An aberrant fusion
protein, WldS, naturally only found in a single mutant mouse
(WldS), can delay Wallerian degeneration markedly [2,3]. Studies
of WldS function have provided considerable insight into the
intrinsic mechanisms involved in the process and have recently led
to the identification of a number of key regulatory molecules and
pathways [4–14]. This includes the finding that NMNAT2, which
shares critical nicotinamide mononucleotide adenylyltransferase
(NMNAT) activity with WldS, is an endogenous axon mainte-
nance factor, with depletion of NMNAT2 in axons likely acting as
a trigger for degeneration [6]. Despite being predominantly
nuclear, a small pool of axonal WldS appears to be responsible for
protection [15–17]. Consequently, because WldS is much more
stable than very short-lived NMNAT2, it has been suggested that
it delays axon degeneration by directly substituting for NMNAT2
loss in compromised axons [6]. However, the relationship between
NMNAT activity and other regulators and/or executers of the
degeneration pathway has yet to be fully established.
Canonical MEK1/2-ERK1/2 signaling, and more recently
MEK5-ERK5 signaling, have been shown to be critical for
neuronal stress responses and/or neurotrophin-mediated neuronal
survival [18–20]. However, a study using the pan-MEK inhibitor
U0126 has also implicated MEK-ERK signaling in the protection
against injury-induced or developmental axon degeneration after
proteasome inhibition [21]. NMNAT2 levels are stabilized after
proteasome inhibition [6], providing one possible explanation for
delayed axon degeneration under these conditions. We therefore
assessed the effects of U0126 on the WldS phenotype to test the
hypothesis that NMNAT activity keeps axons healthy by
sustaining MEK-ERK signaling. As U0126 can inhibit both
MEK1/2 and MEK5 [22,23], we also used more specific small
molecule inhibitors of MEK1/2 and MEK5 to differentiate the
roles of these pathways in relation to axon protection. Surprisingly,
our results appear to rule out involvement of either target.
Results
U0126 can revert the slow Wallerian degeneration (WldS)
phenotype
The ability of the pan-MEK inhibitor U0126 (at 50 mM) to
reverse delayed Wallerian degeneration of neurites in rat superior
cervical ganglion (SCG) cultures after proteasome inhibition
suggested that MEK-ERK signaling might play an important role
in axon maintenance [21]. We therefore investigated whether
MEK-ERK signaling also contributes to the delay of Wallerian
degeneration in WldS neurons.
Neurites in SCG explant cultures from WldS mice are protected
from Wallerian degeneration for at least 72 hours after being
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separated from their cell bodies. In contrast, transected wild-type
neurites begin to degenerate after a short latent phase of just 4–
6 hours [6,12]. We found that 50 mMU0126 partially reverted the
slow Wallerian degeneration phenotype of cut WldS neurites
(Figure 1A and 1B). Neurites treated with U0126 consistently
showed physical signs of degeneration by 24 hours after cut,
whereas untreated transected neurites remained healthy for at
least 48 hours, as expected. Intriguingly, we found that the ability
of U0126 to revert the WldS phenotype appeared highly dose-
dependent but did not fully correlate with inhibition of MEK1/2-
ERK1/2 signaling. ERK1/2 phosphorylation was robustly
inhibited by both 10 mM and 20 mM U0126 (Figure 1C) even
though these doses were much less effective at reverting WldS-
mediated neurite protection (Figure 1A and 1B). Uncut WldS
neurites treated with U0126 remained healthy over the same time-
course (Figure 1D) indicating that this effect was specific to severed
neurites.
Importantly, U0126 can also inhibit the MEK5-ERK5 signaling
pathway [22,23], which is functional in this type of neuron [18].
Consistent with this, we noted a reduction in the proportion of
ERK5 showing retarded electrophoretic mobility after U0126
treatment in these experiments (Figure 1C). Efforts were made to
assess changes in ERK5 phosphorylation directly, but none of the
phosphorylation-dependent antibodies tested were sensitive
enough to specifically detect endogenous levels of the phosphor-
ylated protein. However, retarded electrophoretic mobility of
ERK5 has previously been used as an indicator of ERK5
phosphorylation in SCG neurons [18], and phosphorylation of
the TEY motif in the ERK5 activation loop correlates with
retarded ERK5 electrophoretic mobility in extracts from cell lines
overexpressing components of the MEK5-ERK5 pathway [24].
Interestingly, we found that in addition to full-length ,110 kDa
ERK5 (Figure 1C), SCG neurons also express a ,60 kDa
truncated form of the protein, ERK5-T, which is the result of
alternative splicing [25] (Figure S1). Like full-length ERK5, this
truncated variant can be phosphorylated by MEK5 [25], but we
have so far been unable to detect this in SCG neurons, and
consequently determine its sensitivity to U0126 (data not shown).
Nevertheless, the fact that U0126 inhibits phosphorylation of full-
length ERK5 at concentrations that effectively revert WldS-
mediated axon protection meant that MEK5-ERK5 signaling,
either alone or in combination with MEK1/2-ERK1/2 signaling,
could mediate the effects of WldS.
Combined inhibition of MEK1/2 and MEK5 with
PD184352 and BIX02189 does not replicate the effects of
U0126
In order to define the relative contributions of MEK1/2-
ERK1/2 and MEK5-ERK5 signaling to the slow Wallerian
degeneration (WldS) phenotype we used other, more selective
MEK inhibitors as alternatives to U0126. PD184352 is a highly
selective inhibitor of MEK1/2 [23,26], whilst BIX02189 has
recently been identified as a selective inhibitor of MEK5/ERK5
signaling that fails to inhibit MEK1/2 [27]. Surprisingly, we found
that, unlike U0126, PD184352 and BIX02189 whether alone, or
in combination, did not significantly accelerate degeneration of
transected WldS neurites (Figure 2A and 2B). This was despite the
fact that we confirmed (a) maximal inhibition of each pathway at
the concentrations of PD184352 and BIX02189 used and (b) each
drug exhibited the expected selectivity (Figure 2C). These results
indicated that U0126 reverses the slow Wallerian degeneration
(WldS) phenotype through a mechanism that must be largely
independent of MEK1/2-ERK1/2 or MEK5-ERK5 signaling.
In light of this result, we confirmed the U0126-mediated
reversion of delayed Wallerian degeneration after proteasome
inhibition reported previously [21] and assessed whether this was
also independent of MEK-ERK signaling. Inhibition of protea-
some function with MG-132 three hours prior to cutting resulted
in protection of transected wild-type neurites for at least 6 hours
(Figure 3A and 3B), consistent with previous reports [6,12].
Although the delay in degeneration in this system appears less
robust than that reported using other read-outs [21], we
nevertheless found that U0126 similarly reversed the protection
(Figure 3A and 3B). In contrast, the combined action of PD184352
and BIX02189 had no significant effect (Figure 3A and 3B),
despite again inhibiting ERK1/2 and ERK5 phosphorylation
robustly (Figure 3C). Therefore, our findings suggest that the
ability of U0126 to reverse delayed neurite degeneration after
proteasome inhibition also occurs via a mechanism that is
independent of MEK-ERK signaling.
U0126 does not alter the stability of NMNAT2 or WldS
Reduced turnover of short-lived NMNAT2 has been correlated
with the delay of Wallerian degeneration after proteasome
inhibition in SCG explant cultures and we proposed that WldS
protects neurites because it is relatively much more stable [6]. We
therefore investigated whether U0126 accelerates turnover of
WldS or NMNAT2 to account for its effects on neurite
preservation. We assessed protein stability in a HEK 293T cell
culture-based transfection assay employing a protein synthesis
block which broadly reflects rates of turnover in SCG neurites [6].
We found no evidence for increased turnover of FLAG-WldS
following U0126 treatment (Figure 4A). In addition, proteasome
inhibition stabilized very short-lived FLAG-NMNAT2 after
protein synthesis inhibition, as expected, but this stabilization
was not altered by U0126 (Figure 4B). Therefore, it appears
unlikely that U0126 reverses the slow Wallerian degeneration
phenotype, or delayed Wallerian degeneration after proteasome
inhibition, by reducing levels of WldS or NMNAT2 respectively.
Discussion
A protective or maintenance role for MEK-ERK signaling in
injured axons and during developmental axon pruning was
previously postulated based on the negative effects of the pan-
MEK inhibitor U0126 on neurite health when modeling these
conditions in primary rat SCG cultures [21]. Our finding that
U0126 similarly reverses WldS-mediated protection of severed
mouse SCG neurites initially appeared to support this general
conclusion. However, use of more selective MEK1/2 and MEK5
inhibitors demonstrated that the effects of U0126, both in injured
WldS neurites and injured wild-type neurites after proteasome
inhibition, are independent of MEK/ERK signaling and must
therefore be a consequence of an off-target effect.
Many small molecule kinase inhibitors have unexpected off-
target effects on unrelated kinases [28-30]. Whilst U0126 appears
relatively selective towards MEKs [29,30], the panels of kinases
tested, whilst extensive, were not complete. Therefore the effects of
U0126 seen in this study could be due to as yet uncharacterized
off-target kinase inhibition. We have already provisionally ruled
out reductions in steady-state levels of WldS or levels of NMNAT2
after proteasome inhibition as downstream consequences of such
off-target inhibition, given their critical axonal survival and
maintenance functions. Interestingly, U0126 has previously been
shown to reduce ATP levels in cultured cells resulting in an
increased AMP:ATP ratio and activation of AMPK via what
appears to be a MEK-independent mechanism [31–33]. Since
Axon Protection Does Not Require MEK-ERK Signaling
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Figure 1. Reversion of theWld S phenotype by MEK inhibitor U0126. (A) Representative phase contrast images of transected neurites inWldS
SCG explant cultures treated with different concentrations of U0126 as indicated (untreated = DMSO). Images of the same field of distal neurites
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declining ATP levels might contribute to the initiation or
execution of Wallerian degeneration [34], a U0126-mediated
reduction in ATP could thus account for its effects on preservation
of transected axons, although PD184352 may have similar off-
target effects in some cell types [31]. Interestingly, mitochondrial
ATP production and Ca2+ buffering have respectively been shown
were captured at the times after transection shown on the left. (B) Quantification of neurite degeneration for transected WldS neurites as in (A).
Degeneration index (6 SEM) was calculated from multiple fields in n = 4 independent experiments. * p,0.05, ** p,0.01, and *** p,0.001, 2-way
repeated measures ANOVA with Tukey’s multiple comparisons post hoc tests. All statistically significant differences are marked. All other comparisons
were not significant. (C) Representative immunoblots showing inhibition of ERK1/2 and ERK5 phosphorylation in whole WldS SCG explant cultures
(cell bodies and neurites combined) 48 hours after treatment with different concentrations of U0126. Phosphorylated ERK1/2 was detected using a
phosphorylation-dependent antibody. Phosphorylated ERK5 was detected as a slower migrating band (indicated by an arrow) using a
phosphorylation-independent antibody. Total ERK1/2 and ERK5 levels act as sample references. (D) Representative phase contrast image (left)
showing cut and uncut neurites in WldS SCG explant cultures 48 hours after transection and treatment with 50 mM U0126. Boxed regions are
magnified to show morphology of cut and uncut neurites.
doi:10.1371/journal.pone.0076505.g001
Figure 2. MEK1/2 inhibitor PD184352 and MEK5 inhibitor BIX02189 fail to revert the Wld S phenotype. (A) Representative phase
contrast images of transected neurites in WldS SCG explant cultures treated with U0126 (50 mM), PD184352 (5 mM) and/or BIX02189 (10 mM) as
indicated (untreated = DMSO). Images of the same field of distal neurites were captured just after transection and 48 hours later. (B) Quantification
of neurite degeneration for transected WldS neurites as in (A). Degeneration index (6 SEM) was calculated from multiple fields in n= 3 or 4
independent experiments. * p,0.05, ** p,0.01 and *** p,0.001, 2-way repeated measures ANOVA with Tukey’s multiple comparisons post hoc tests.
All statistically significant differences are marked. All other comparisons were not significant. (C) Representative immunoblots showing inhibition of
ERK1/2 and ERK5 phosphorylation in whole WldS SCG explant cultures (cell bodies and neurites combined) after 48 hours treatment with U0126
(50 mM), PD184352 (5 mM) and/or BIX02189 (10 mM) as indicated (untreated = DMSO). Phosphorylated ERK1/2 was detected using a
phosphorylation-dependent antibody. Phosphorylated ERK5 was detected as a slower migrating band (indicated by an arrow) using a
phosphorylation-independent antibody. Total ERK1/2 and ERK5 levels act as sample references.
doi:10.1371/journal.pone.0076505.g002
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to be enhanced in WldS mice and in transgenic flies expressing
WldS [35,36]. Given the established link between mitochondrial
Ca2+ levels and ATP generation [37], this raises the possibility that
the critical off-target effect of U0126 in this study might be to
influence mitochondrial Ca2+ homeostasis in some way. However,
a recent report suggesting that mitochondria are not required for
WldS-mediated axon protection in flies [38], seems to challenge
this idea.
Our finding that U0126 does not affect the short-term
maintenance and survival of uninjured WldS neurites is in
agreement with the previous finding that it only impacts delayed
degeneration of severed or otherwise compromised wild-type
neurites [21]. Irrespective of any off-target effects of U0126, this
clearly indicates that loss of ERK1/2 and ERK5 signaling is not
sufficient to induce spontaneous degeneration of intact neurites.
Declining ERK1/2 phosphorylation, which appears to precede
loss of total ERK1 in transected wild-type neurites [21], could
Figure 3. Delayed Wallerian degeneration after proteasome inhibition is not reverted by PD184352 and BIX02189 combined. (A)
Representative phase contrast images of transected wild-type neurites in SCG explant cultures treated with U0126 (50 mM), or PD184352 (5 mM) plus
BIX02189 (10 mM) combined, after proteasome inhibition by MG-132 (20 mM) (untreated = DMSO). Images of the same field of distal neurites were
captured just after transection and 6 hours later. (B) Quantification of neurite degeneration for transected neurites as in (A). Degeneration index (6
SEM) was calculated from multiple fields in n= 3 independent experiments. ** p,0.01, 2-way repeated measures ANOVA with Tukey’s multiple
comparisons post hoc tests. All statistically significant differences are marked. All other comparisons were not significant. (C) Representative
immunoblots showing inhibition of ERK1/2 and ERK5 phosphorylation in whole wild-type SCG explant cultures (cell bodies and neurites combined) 9
hours after proteasome inhibition by MG-132 (20 mM) and 6 hours after treatment with U0126 (50 mM), or a combination of PD184352 (5 mM) plus
BIX02189 (10 mM) (untreated = DMSO). Phosphorylated ERK1/2 was detected using a phosphorylation-dependent antibody. Phosphorylated ERK5
was detected as a slower migrating band (indicated by an arrow) using a phosphorylation-independent antibody. Total ERK1/2 and ERK5 levels act as
sample references.
doi:10.1371/journal.pone.0076505.g003
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nevertheless still contribute to the progression of Wallerian
degeneration, but the possibility that this is simply an early
consequence of the degeneration process itself also cannot be ruled
out.
We conclude that MEK-ERK signaling, specifically through
MEK1/2 or MEK5, is not required for the preservation of
transected neurites by WldS or proteasome inhibition. Rather, the
widely-used MEK inhibitor U0126 appears to reverse this
protection via an as yet unidentified target. Importantly, this
study highlights the risk of interpreting results based solely on data
obtained with this compound. Reassessment of findings using
more selective MEK1/2 and MEK5 inhibitors, such as PD184352
and BIX02189, should be performed as standard and could lead to
important new insights into cellular signaling.
Materials and Methods
Ethical treatment of animals
All animal work was carried out in strict accordance with the
UK Animals (Scientific Procedures) Act, 1986, under Project
Licenses PPL 80/1778 and 80/2254 and was approved by the
Babraham Institute Animal Welfare, Experimentation and Ethics
Committee. Postnatal day 1 or 2 (P1 or P2) mouse pups were
sacrificed by decapitation, with every effort made to limit suffering.
Cell culture
Superior cervical ganglia were dissected from P1 or P2 mouse
pups. Cleaned explants were placed in the center of 3.5 cm tissue
culture dishes pre-coated with poly-L-lysine (20 mg/ml for 1–
2 hours; Sigma) and laminin (20 mg/ml for 1–2 hours; Sigma).
Explants were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM) with 4500 mg/L glucose and 110 mg/L sodium
pyruvate (Sigma), 2 mM glutamine, 1% penicillin/streptomycin,
100 ng/ml 7S NGF (all Invitrogen), and 10% fetal bovine serum
(Sigma). 4 mM aphidicolin (Calbiochem) was used to reduce
proliferation and viability of non-neuronal cells. Experiments were
performed after 5–7 days in vitro.
C57BL/6JOlaHsd and homozygous C57BL/6OlaHsd-Wld
(WldS) mice were originally obtained from Harlan UK (Bicester,
UK) and maintained as a long-term breeding colony at the
Babraham Institute.
HEK 293T cells were cultured under standard conditions in
DMEM with 4500 mg/L glucose and 110 mg/L sodium pyruvate
(PAA), supplemented with 2 mM glutamine and 1% penicillin/
streptomycin (both Invitrogen), and 10% fetal bovine serum
(Sigma).
Inhibitor treatments
The MEK inhibitors U0126 (Promega), PD184352 (Selleck),
and BIX02189 (a kind gift from Roger Snow, Boehringer
Figure 4. U0126 does not alter FLAG-NMNAT2 or FLAG-WldS turnover in transfected HEK 293T cells. Immunoblot analyses assessing the
effects of U0126 (50 mM) on natural turnover of FLAG-WldS (A) and stabilization of FLAG-NMNAT2 after proteasome inhibition (B) in HEK 293T cells.
Cells were co-transfected with FLAG-WldS and FLAG-NMNAT2 expression constructs. 24 hours after transfection cells were treated with emetine
(10 mM), together with proteasome inhibitor MG-132 (20 mM) and/or U0126 (50 mM), as indicated, for a further 24 hours. Control cells (–) treated with
DMSO were collected at the time of emetine addition (0 hours) to act as a reference for expression levels before protein synthesis was blocked. ß-
Actin acts as the sample reference. Blots of FLAG-NMNAT2 and FLAG-WldS in (A) and (B) respectively (bottom panels) are included only as controls
(for transfection efficiency or emetine efficacy). Representative images are shown. Relative mean levels (6 SEM) of FLAG-WldS (A) and FLAG-NMNAT2
(B) are shown below the relevant lanes on each blot after normalization to ß-Actin (based on data from n= 2 and n= 4 respectively). Data are
presented relative to the DMSO controls (–) (set at 1).
doi:10.1371/journal.pone.0076505.g004
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Ingelheim) were dissolved in DMSO as 10 mM stock solutions and
diluted in media as required. InSolution MG-132 (Calbiochem)
was added to SCG explant cultures at a final concentration of
20 mM 3 hours prior to neurite transection. This pre-treatment is
required to see neurite protection in these cultures [6,12].
Quantification of transected neurite degeneration
Neurites were cut with a disposable scalpel roughly half-way
between their cell bodies and their most distal ends. Inhibitors or
vehicle (DMSO) were added to the media less than 10 minutes
before transection. Phase contrast images of transected neurites
were captured on an Olympus IX81 inverted microscope using a
Soft Imaging Systems (SIS) F-View camera linked to a PC running
the appropriate SIS imaging software and 10x or 20x objectives.
Images of the same field of transected neurites were captured at
different time points after cut. Images were processed for
manuscript presentation using Adobe Photoshop Elements 4.0.
Neurite degeneration was quantified as a Degeneration Index
essentially as described previously [39], except that for calculating
the area representing degenerated axon fragments using the
ImageJ Particle Analyzer function a size range of 20–350 pixels
was used for images captured with the 20x objective (total image
size = 137661032 pixels).
Immunoblot analysis
Whole SCG explant extracts were collected at the end of each
experiment as indicated in the figure legends. Cell bodies and
proximal neurites were combined with transected neurites to
provide sufficient non-degenerated material for assessment of the
effects of inhibitors on ERK1/2 and ERK5 phosphorylation.
HEK 293T cells at 60–80% confluence in 12-well plates were co-
transfected with 100 ng FLAG-WldS and 250 ng FLAG-
NMNAT2 expression constructs (described previously [6]) per
well using Lipofectamine 2000 reagent (Invitrogen). Twenty-four
hours after transfection cells were treated with inhibitors as
described. In both cases cells were washed in cold PBS containing
cOmplete Mini protease inhibitor cocktail (Roche) prior to lysis
directly into 2x Laemmli sample buffer.
Extracts were separated by standard SDS-PAGE on 6 or 12%
gels (depending on the proteins being detected) and transferred to
Immobilon-P membrane (Millipore) or nitrocellulose (for ERK5
detection) using the Bio-Rad Mini-PROTEAN III wet transfer
system. Blots were blocked and incubated with primary antibodies
overnight at 4uC in 1x TBS p.H. 8.3 with 0.05% Tween 20 and
5% milk powder, followed by the appropriate HRP-conjugated
secondary antibody (1 hour room temperature at 1:2000–1:5000)
and detection by ECL or ECL plus (GE Healthcare), with washes
between each stage. Antibody-specific instructions provided by the
supplier were followed for detection of ERK5. The following
primary antibodies were used; mouse monoclonal anti-FLAG M2
(1:2000, Sigma), rabbit polyclonal Wld18 anti-WldS (1:4000),
mouse monoclonal anti-ß-Actin clone AC-74 (1:5000, Sigma
A5316), rabbit polyclonal anti-BMK1/ERK5 (1:750, Upstate/
Millipore 07-039), mouse monoclonal anti-ERK1 (1:2000, BD
Transduction Laboratories 610031) which also recognizes ERK2,
and mouse monoclonal anti-phospho-ERK1/2 (1:2000, Cell
Signaling Technology 9106).
Statistical analysis
Data are presented as mean 6 SEM. The statistical analyses
described in the text were performed using Microsoft Excel and
Prism (GraphPad Software Inc., La Jolla, CA, USA) software.
Differences were considered statistically significant if p,0.05.
Supporting Information
Figure S1 SCG neurons express the truncated ERK5
splice variant, ERK5-T. (A) Erk5 mRNA encodes 806 amino
acid ERK5. Failure to remove intron 4 in the Erk5-T splice variant
introduces an alternative termination codon resulting in a
truncated protein of 502 amino acids that shares the N-terminal
492 amino acids with ERK5 (protein lengths indicated here do not
include the termination codon) [25]. (B) RT-PCR analysis of SCG
mRNA using primers flanking intron 4 in Erk5-T mRNA (5’-
CCTCCAGCACTGCCACCAT-3’ and 5’-CGCTTCTCTTCT
CGTTCTCG-3’). A product of 260 bp was amplified from Erk5
mRNA, lacking the 103 bp intron 4, and a product of 363 bp was
amplified from Erk5-T mRNA. Erk5-T mRNA appears to be
significantly less abundant than Erk5 mRNA. RT-PCR was
performed as described previously [6]. (C) Immunoblot analysis
using antibodies (Biosource MBS615166 and SantaCruz ERK5 N-
19) raised against conserved epitopes in ERK5-T (shared with
ERK5). A ,60 kDa band, corresponding to the expected size of
ERK5-T, was detected by both antibodies in the SCG extract but
was absent from Erk52/2 mouse embryo fibroblasts (MEFs). Both
antibodies failed to detect endogenous levels of full-length ERK5
in the SCG extract (even though Erk5 mRNA appears more
abundant than Erk5-T mRNA), but did detect stably overex-
pressed exogenous ERK-5 (HA-tagged). Both antibodies cross-
reacted with several non-specific bands. The most intense cross-
reacting bands are marked (*). A different antibody (Upstate/
Millipore, 07-039) was used to detect full-length ERK5 in SCGs
(Figures 1, 2 and 3). This was raised against C-terminal amino
acids (783-806) in human ERK5 that are not present in ERK5-T.
(TIF)
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